Abstract-Angiotensin (Ang)-(1-7) is a biologically active peptide of the renin-angiotensin system that has both vasodilatory and antiproliferative activities that are opposite the constrictive and proliferative effects of angiotensin II (Ang II). We studied the actions of Ang-(1-7) on the Ang II type 1 (AT 1 ) receptor in cultured rat aortic vascular smooth muscle cells to determine whether the effects of Ang-(1-7) are due to its regulation of the AT 1 receptor. Ang-(1-7) competed poorly for 
A ngiotensin (Ang)-(1-7), the amino-terminal angiotensin heptapeptide, is an important biologically active peptide of the renin-angiotensin system (RAS). 1 Ang-(1-7) plays a role in vascular regulation that is distinct and often opposite that of angiotensin II (Ang II). Furthermore, these opposing effects of Ang II and Ang-(1-7) occur at similar concentrations of the 2 angiotensin peptides. For example, in contrast to the mitogenic effects of nanomolar Ang II, Ang-(1-7) inhibits vascular smooth muscle cell (VSMC) growth with an IC 50 value in the nanomolar range. 2 Ang-(1-7) reduces neointimal formation after vascular injury and increases urinary prostaglandin release at concentrations of the heptapeptide 2-to 3-fold higher than the endogenous circulating concentration of Ang-(1-7) or Ang II. 3, 4 Nanomolar concentrations of Ang-(1-7) increased arachidonic acid release and prostacyclin production in rabbit VSMCs, with maximal effects observed at 100 nmol/L Ang-(1-7). 5 Ang-(1-7) stimulated prostaglandin (PG)E 2 and prostacyclin release from both porcine and rat VSMCs with EC 50 values in the nanomolar range. 6, 7 Finally, Ang-(1-7) caused the vasodilation of rabbit renal afferent arterioles at nanomolar concentrations of the heptapeptide. 8 In addition, the actions of endogenous Ang-(1-7) unmasked after converting enzyme inhibition 9 or a low-salt diet 10 appear to occur at submicromolar concentrations of the heptapeptide. These results indicate that Ang-(1-7) has both vasodilatory and antiproliferative effects that are observed at subpharmacological concentrations of the heptapeptide.
In contrast, various effects of Ang-(1-7) were reported at pharmacological doses of the heptapeptide. We observed a rapid transient increase in pressure preceding a more prolonged depressor response when high doses of Ang-(1-7) were injected into pithed rats. 11 The pressor, but not the depressor, component of this response was blocked by the AT 1 receptor antagonist losartan, suggesting that high concentrations of Ang-(1-7) may stimulate the AT 1 receptor to increase blood pressure. Mahon et al 12 reported that micromolar concentrations of Ang-(1-7) caused a rightward shift in the dose-contractile response to Ang II in rabbit aortic rings and a concentration-dependent decrease in the maximal response, with a pA 2 of 5.5, and suggested that Ang-(1-7) was an antagonist at the AT 1 receptor at micromolar concentrations of the heptapeptide. Roks et al 13 also demonstrated that Ang-(1-7) at a concentration of 10 mol/L reduced Ang Iand Ang II-induced contraction of human internal mammary arteries, suggesting that micromolar Ang-(1-7) was an antagonist at the AT 1 receptor. Because Ang-(1-7) competes for binding to the vascular AT 1 receptor at micromolar concentrations, 7 pharmacological concentrations of Ang-(1-7) may oppose or counteract the actions of Ang II through competitive antagonism. Alternatively, Ang-(1-7) could oppose the vasoconstrictive and proliferative effects of Ang II through downregulation or desensitization of the AT 1 receptor. This study was designed to determine whether Ang-(1-7) causes a downregulation of the AT 1 receptor or desensitizes responses to Ang II by direct actions at the AT 1 receptor. 
Methods

Materials
Cell Culture Procedures
Aortic VSMCs were isolated from 10-to 12-week-old male Hannover Sprague-Dawley rats bred and raised at the ALACCaccredited animal facility of Wake Forest University School of Medicine. Primary cultures of VSMCs were obtained from aortic explants as previously described. 2 The cells were cultured in DMEM/F12 supplemented with 10% FBS, 100 g/mL penicillin, and 100 U/mL streptomycin and maintained at 37°C in a humidified CO 2 incubator (5% CO 2 and 95% air). Confluent monolayers of VSMCs from passages 4 to 9 were used in all experiments.
Measurement of [ 125 I]Ang II Binding
Ang II was iodinated according to a modified chloramine T procedure, and the monoiodinated form was purified through HPLC according to previously established procedures. 14 After a 1-hour incubation at room temperature, binding reactions were terminated by aspirating the binding buffer from individual wells and washing each well with ice-cold PBS (2 mL/wash). Cellular proteins were solubilized in 2N NaOH, and cell-associated radioactivity was quantified with ␥-spectroscopy. Protein was measured according to the Lowry method 15 with BSA used as the standard.
Various types of binding studies were conducted to determine competition by peptides and antagonists, the effect of pretreatment with angiotensin peptides on subsequent Ang II binding, and saturation isotherms to calculate binding constants, as described here.
First, competition studies were performed by incubating VSMCs with increasing concentrations (from 10 
Measurement of Phosphoinositide-Specific Phospholipase C
Phospholipase C (PLC) activity was assayed by the production of 3 H-labeled inositol phosphates in VSMCs prelabeled with myo-3 Hinositol, as previously described. 16 Confluent monolayers of VSMCs in 6-well culture plates were labeled for 72 hours with myo- 
Results
Competition for the AT 1 Receptor by Ang-(1-7)
VSMCs were incubated with increasing concentrations of Ang II and Ang-(1-7) to determine whether Ang-(1-7) competed for 
Regulation of the AT 1 Receptor by Ang-(1-7)
Ang II binds to AT 1 receptors on VSMCs and induces a rapid internalization of the Ang II-AT 1 receptor complex. Because we observed that Ang-(1-7) binds to the vascular AT 1 receptor, albeit at a 1000-fold higher concentration than Ang II, Ang-(1-7) binding to the AT 1 (Table) . In contrast, pretreatment with 1 mol/L Ang-(1-7) for 30 minutes caused a significant 66Ϯ8% decrease in the B max of Ang II receptors on VSMCs.
Effect of AT 1 Receptor Antagonism on AT 1 Receptor Downregulation
The AT 1 receptor antagonist L-158,809 was used to further demonstrate that the reduction in 
Effect of Ang-(1-7) on Ang II-Induced PLC Activity
Ang II significantly stimulated inositol phosphate release from VSMCs, measured as the release of total inositol phosphates from cells prelabeled with myo-3 H-inositol. A 30-minute incubation of VSMCs with Ang II (10 nmol/L) increased phosphoinositide-specific PLC activity by 102.6Ϯ19.6% above basal levels (PϽ0.05, nϭ5). A similar incubation with 1 mol/L Ang-(1-7) had no effect on inositol phosphate release (85.8Ϯ8.7% of basal level, nϭ5). However, a 30-minute pretreatment with concentrations of Ang-(1-7) of 0.1 to 10 mol/L, followed by a 30-minute incubation with 10 nmol/L Ang II, resulted in a dose-dependent decrease in Ang II-stimulated PLC activity, with a significant decrease to 81.2Ϯ6.4% above basal levels (PϽ0.01, nϭ5) at 1 mol/L Ang-(1-7) and to 38.4Ϯ7.0% above basal levels (PϽ0.01, nϭ5) at 10 mol/L Ang-(1-7) as shown in Figure 4 .
Effect of Ang-(1-7) on the Binding Affinity and Density of the AT 1 Receptors on VSMCs
Discussion
The pretreatment of VSMCs with Ang-(1-7) followed by treatment with acidic glycine to remove surface-bound peptide reduced subsequent binding of Ang II to the AT 1 receptor. However, the decrease in Ang II binding was detected only at micromolar concentrations of the heptapeptide, which is in agreement with the micromolar affinity of Ang-(1-7) for the AT 1 receptor. The reduction in Ang II binding by Ang-(1-7) resulted from a decrease in the number of receptors available for subsequent binding with no significant effect on receptor affinity. The downregulation of the Ang II receptor by Ang-(1-7) was blocked by pretreatment with the AT 1 receptor antagonist L-158,809, demonstrating that micromolar concentrations of Ang-(1-7) have direct effects at the AT 1 receptor to reduce the number of receptors available for subsequent binding. Finally, Ang-(1-7) , at a concentration of 1 mol/L, significantly attenuated the Ang II-mediated stimulation of PLC to reduce the production of inositol phosphates. These results clearly demonstrate that the short-term treatment of VSMCs with pharmacological concentrations of Ang-(1-7) downregulates the vascular AT 1 receptor.
Although 1 mol/L Ang-(1-7) alone did not activate PLC in VSMCs, it did reduce subsequent binding of Ang II to the AT 1 receptor and attenuated activation of AT 1 -coupled cellular responses by Ang II. The AT 1 receptor on VSMCs is rapidly internalized on stimulation by Ang II, a phenomenon accompanied by a reduction in subsequent responses. This suggests that Ang-(1-7), at micromolar concentrations, binds to the AT 1 receptor to induce receptor internalization without activating subsequent cellular responses. Previous work with substance P and serotonin receptors clearly indicates that receptor internalization can occur independent of changes in functional responsiveness. [17] [18] [19] Studies by several investigators suggest that different motifs in the structure of the AT 1 receptor are required for receptor internalization compared with intracellular signal generation by Ang II. 20 -22 The truncation of a section of the carboxyl terminus of the AT 1A receptor prevented receptor internalization without affecting coupling to PLC. 21, 23 A point mutation in the AT 1 receptor that eliminates Ang II coupling to PLC (Asp 74 3 Asn) did not block receptor internalization. 22 In addition, the potent antagonist [Sar 1 ,Ile   8 ]Ang II, a sarcosine analog of Ang II, was internalized but did not activate PLC in Chinese hamster ovary cells transfected with the AT 1 receptor, as well as in adrenal medullary cells. 22, 24 This suggests that Ang-(1-7), as well as sarcosine analogs of Ang II, bind to and activate the AT 1 receptor to produce receptor internalization without coupling to G proteins to activate PLC. In contrast, the nonpeptide antagonist L-158,809 did not cause internalization in our study. Thus, it is possible that high concentrations of Ang-(1-7) and the peptide antagonists produce receptor internalization through weak agonist properties. This would also be consistent with our observation of a weak pressor response to high doses of Ang-(1-7) in the pithed rat, an effect that was mediated by an AT 1 receptor. 11 Mahon et al 12 suggested that Ang-(1-7) is a noncompetitive antagonist at AT 1 receptors in rabbit aortic rings, causing a rightward shift in the dose-response contraction curve to Ang II administered 60 minutes after Ang- (1-7) . However, the concentrations of Ang-(1-7) used in their study ranged from 1 to 30 mol/L. Roks et al 13 also suggested that 10 mol/L Ang-(1-7) was antagonistic at the AT 1 receptor in human VSMCs. This would be consistent with our observation that Ang-(1-7) had an IC 50 value of 2 mol/L at the AT 1 receptor in VSMCs. Our evidence suggests that short-term exposure of cells to micromolar levels of Ang-(1-7) downregulates the AT 1 receptor over a time frame consistent with receptor internalization. Thus, when Ang II is given after a prior exposure to Ang-(1-7) (as we did in our study) or in the presence of a large excess of Ang-(1-7) (as in studies described by Roks et al 13 and Mahon et al 12 ) , one might expect antagonist actions of Ang-(1-7). However, endogenous circulating levels of Ang-(1-7), as well as tissue concentrations of the peptide, are in the picomolar range. [25] [26] [27] Although treatment with ACE inhibitors increased circulating levels of Ang-(1-7) from 9-to 25-fold, 25, 28 there is no evidence showing an increase in endogenous Ang-(1-7) levels to the micromolar range. In addition, the majority of the in vivo and in vitro actions of Ang-(1-7) occur at doses lower than 1 to 30 mol/L. Because Ang-(1-7) downregulated Ang II binding and receptor activation only at micromolar concentrations, the vasodilatory and antiproliferative responses that occur at nanomolar concentrations of the heptapeptide cannot be explained by antagonist effects of Ang-(1-7) at the AT 1 receptor. Ueda et al 29 recently reported that the infusion of Ang-(1-7) antagonized the Ang IImediated vasoconstriction of human forearm resistance vessels, suggesting that Ang-(1-7) is an endogenous antagonist of the human AT 1 receptor. However, the authors reported that Ang-(1-7) significantly reduced the response to Ang II at a dose of 10 nmol/L, a concentration significantly lower than the IC 50 value for the AT 1 receptor (Ͼ1 mol/L). In light of our observations, the responsiveness to Ang-(1-7) in the study by Ueda et al 29 may be due to activation of a non-AT 1 receptor by Ang-(1-7) and the release of a compensatory vasodilator such as NO or prostaglandins.
In addition, evidence from several studies clearly shows that the actions of Ang-(1-7) are independent of AT 1 receptor activation. The vasodilation of canine or porcine coronary arteries induced by Ang-(1-7) was prevented by removal of the endothelium or by blockade of NO release, 30, 31 suggesting that Ang-(1-7) stimulated NO production to counter the vasoconstrictor effects of Ang II. These effects were not blocked by AT 1 or AT 2 receptor antagonists. Muthalif et al 5 showed that Ang-(1-7) stimulated arachidonic acid release from rabbit VSMCs, an effect that was partially prevented by [D-Ala 7 ]Ang-(1-7), the selective Ang-(1-7) receptor antagonist, or by the AT 2 antagonist PD 123319 but not by an AT 1 receptor antagonist. Ang-(1-7) caused the vasodilation of renal afferent arterioles, an effect blocked by [D-Ala 7 ]Ang-(1-7). 8 Further, Ang-(1-7) blocked mitogen-stimulated growth of rat VSMCs, responses that were not reversed by an AT 1 or AT 2 receptor antagonist 2 but were prevented by the selective Ang-(1-7) receptor antagonist [D-Ala 7 ]Ang-(1-7), 32 suggesting that Ang-(1-7) activates a unique receptor on VSMCs to counteract the mitogenic response to Ang II. These in vitro studies are further supported by observations in combined ACE inhibitor/losartan-treated rats where a monoclonal antibody to Ang-(1-7) 9 or [D-Ala 7 ]Ang-(1-7) 33 unmasked a role for endogenous Ang-(1-7), working in part through prostaglandins, in the blood pressure-lowering effects. 34 Furthermore, there is evidence for a [D-Ala 7 ]Ang-(1-7)-sensitive, non-AT 1 , non-AT 2 receptor in the aorta 32 and mesentery 34 of the animals treated with ACE inhibitors and losartan. Thus, Ang-(1-7) has unique effects in the vasculature that are coupled to a non-AT 1 receptor and do not result from antagonism of the AT 1 receptor.
In the present study, we showed that prior treatment of VSMCs with Ang-(1-7) attenuated [ 125 I]Ang II binding to the AT 1 receptor and reduced Ang II-stimulated PLC activation. However, significant downregulation of Ang II binding and Ang II-mediated responsiveness occurred only at micromolar concentrations of Ang-(1-7), in agreement with its IC 50 value for competition at the AT 1 receptor. These results suggest that at micromolar concentrations, Ang-(1-7) acts as a weak agonist at the AT 1 receptor to downregulate the receptor and to reduce subsequent cellular responses to Ang II.
